Compare ClearPoint Neuro Inc (CLPT) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Raymond James Financial, Inc. — how do they compare? ClearPoint Neuro Inc trades at $15.97 (market cap $478.63M), while Raymond James Financial, Inc. trades at $170.85 (market cap $32.63B). The key difference: Raymond James Financial, Inc. is far larger — about 68.2× ClearPoint Neuro Inc's market cap, and Raymond James Financial, Inc. pays a 1.29% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | RJF | |
|---|---|---|
Market Cap | $478.63M | $32.63B |
Sector | Health | Financials |
52-Week High | $29.60 | $176.43 |
52-Week Low | $8.66 | $140.89 |
Enterprise Value | $506.63M | — |
Dividend Yield | — | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
Raymond James Financial (RJF) trades at $166.98, down 0.68% on the day, with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.83 surpassing expectations of $2.76, and revenue growth from $10.9B in 2022 to $13.84B in 2025. Analyst consensus is positive with a $176.83 price target, and recent news highlights momentum and dividend declarations.
The outlook for RJF remains favorable due to earnings momentum and analyst support, though risks include expense pressures and market volatility. Investment opportunity lies in its valuation below consensus target and dividend growth, but investors should monitor cost management and economic conditions that could impact financial services demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
